Boehringer Ingelheim Corporation Release: National Institute for Clinical Excellence (NICE) Issues Final Appraisal Determination (FAD) with Unrestricted Recommendation for Pradaxa® (dabigatran etexilate) for Patients with Non-Valvular Atrial Fibrillation1
11/2/2011 7:44:47 AM
INGELHEIM, Germany--(BUSINESS WIRE)--For NON-US, UK & Canada Media Only
The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has issued a Final Appraisal Determination (FAD)1 recommending the novel oral anticoagulant, Pradaxa® (dabigatran etexilate), as a treatment option without any restrictions within its licensed indication for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (AF) with one or more risk factors.* The FAD will form the guidance to the National Health Service (NHS) in England and Wales, which is expected to be published in December.
comments powered by